SEC Comment Letter 0000000000-25-000095 to FibroBiologics, Inc. (FBLG)
FibroBiologics, Inc.
Date: Jan. 6, 2025 · CIK: 0001958777 · Accession: 0000000000-25-000095
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284077
Letter
January 6, 2025 Pete O'Heeron Chief Executive Officer FibroBiologics, Inc. 455 E. Medical Center Blvd. Suite 300 Houston, TX 77598 Re:FibroBiologics, Inc. Registration Statement on Form S-1 Filed December 30, 2024 File No. 333-284077 Dear Pete O'Heeron: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Brian P. Fenske, Esq.
Show Raw Text
January 6, 2025
Pete O'Heeron
Chief Executive Officer
FibroBiologics, Inc.
455 E. Medical Center Blvd.
Suite 300
Houston, TX 77598
Re:FibroBiologics, Inc.
Registration Statement on Form S-1
Filed December 30, 2024
File No. 333-284077
Dear Pete O'Heeron:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Brian P. Fenske, Esq.